1-[3-(3,3-Dimethylbutanoyl)phenyl]pyrrolidine-2,5-dione

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[3-(3,3-Dimethylbutanoyl)phenyl]pyrrolidine-2,5-dione
• 英文别名: 1-[3-(3,3-dimethylbutanoyl)phenyl]pyrrolidine-2,5-dione
• 化学式: C₁₆H₁₉NO₃
• 分子量: 273.33
• InChiKey: RBPOGNKJTOJOIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• HYDROPHILIC SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF
  申请人：BioAlliance C.V.

  公开号：US20140193437A1

  公开（公告）日：2014-07-10

  The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.
• ANTI-FOLATE RECEPTOR ALPHA (FRA) ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF
  申请人：BIOALLIANCE C.V.

  公开号：US20160015827A1

  公开（公告）日：2016-01-21

  The present disclosure provides anti-folate receptor alpha (FRA) antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.
• HER2 ANTIBODY-DRUG CONJUGATES
  申请人：AbGenomics International Inc.

  公开号：US20160051695A1

  公开（公告）日：2016-02-25

  The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleaved under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker. In some aspects of the present disclosure, the targeting moiety is an anti-HER2 antibody. The present disclosure further provides compositions and methods for treating cancers.
• ANTI-CD22 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THEREOF
  申请人：BioAlliance C.V.

  公开号：US20160015831A1

  公开（公告）日：2016-01-21

  The present disclosure provides anti-CD22 antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.
• US9089614B2
  申请人：——

  公开号：US9089614B2

  公开（公告）日：2015-07-28